NanoViricides Inc (NNVC)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$1.38-3.50%
Close 2026-11-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NNVC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 65 industry peers
NNVC — debt issuance
Dated 2026-07-30
Entry into a Material Definitive Agreement. Securities Purchase Agreement On July 24, 2026, NanoViricides, Inc. (the “Company”) and a certain purchaser (the “Investor”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) pursuant to which the Company agreed to sell and issue to the Investor in a registered direct offering (the “Offering”): (i) 2,416,339 shares of common stock, par value $0.00001 per share (the “Common Stock”), at an offering price of $1.53 per s…
Why it matters: NV-387 is the company's lead antiviral. A clinical update would show whether work has moved beyond animal studies.
Supportive ifThe company names a new clinical trial step, gives a start date, or reports patient data for NV-387.
Worry ifThe next company update gives no new trial step or patient data for NV-387.
Why it matters: NNVC's signals show losses and high risk, while major drug peers show stronger business signals. Its report can show if that gap is narrowing.
Watch forThe report shows lower losses than the prior quarter and gives a dated NV-387 trial milestone.
Also watch forThe report shows higher losses than the prior quarter and gives no dated NV-387 trial milestone.
Why it matters: The company raised about $5.8 million in two 2026 offerings and still reports losses. The next report can show how long its cash may last.
Watch forThe November 13 report gives cash on hand and shows quarterly net losses below $2.22 million.
Also watch forThe report shows quarterly net losses over $2.22 million. Or it says another offering is needed soon.
Why it matters: The company raised about $2 million in May and $3.8 million in July. Another sale may add cash but also issue more shares or warrants.
Worry ifThe company announces a new share or warrant sale after the July 2026 sale.
Less concerning ifNo new share or warrant offering is announced through the next two quarterly reports.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$282 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $826 loss on $10,000 · 8.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,685 loss on $10,000 · 56.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.